EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience



Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience



Seminars in Hematology 37(1): 69-80



Patients with severe aplastic anemia (SAA) can be successfully treated with bone marrow transplantation (BMT) or immunosuppressive therapy (IS). The current outcome using both forms of therapy among 3,669 patients treated in Europe between 1976 and 1998 is reviewed. Significant progress has been made and the overall risk of failure is now low, with survival rates greater than 80% for both treatments. Chronic graft-versus-host disease (GvHD) remains a problem for BMT patients, and carries a high risk of lethal complications. On the other hand, IS patients are exposed to late failure due to relapse or clonal/malignant diseases. First-line BMT from identical siblings is compared with IS therapy in an intent-to-treat analysis of 1,765 patients, regardless of subsequent transplant status. The outcome of SAA patients has improved considerably over time and is influenced by patient variables such as severity of the disease and age, but also by the choice of the initial treatment.

(PDF same-day service: $19.90)

Accession: 035980722

Download citation: RISBibTeXText

PMID: 10676912

DOI: 10.1016/s0037-1963(00)90031-3



Related references

Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematologica 103(1): 19-25, 2000

Bone marrow transplantation or immunosuppressive therapy for patients with severe aplastic anemia A report of the European Group for Blood and Marrow Transplantation. Blood 92(10 SUPPL 1 PART 1-2): 158A, Nov 15, 1998

Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica The Hematology Journal 92(1): 11-18, 2007

Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European group for blood and marrow transplantation. Acta Haematologica (Basel) 103(1): 19-25, March, 2000

The crux of the log rank test. Re: Locasciulli A, Oneto R, Bacigalupo A, Socie G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, Fuhrer M. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation. Haematologica 2007; 92:11-8. Haematologica 92(12): E122-E122, 2007

Severe acquired aplastic anemia in children: 11-year experience with bone marrow transplantation and immunosuppressive therapy. American Journal of Pediatric Hematology/Oncology 11(3): 304-309, 1989

Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Annals of Internal Medicine 130(3): 193-201, 1999

Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biology of Blood and Marrow Transplantation 17(1): 78-85, 2011

Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Working Party on Severe Aplastic Anaemia of the European Blood and Marrow Transplantation Group. European Journal of Haematology. Supplementum 60: 16-19, 1996

Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Annals of Internal Medicine 126(2): 107-115, 1997

Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. International Journal of Hematology 104(2): 168-174, 2016

Comparison of bone marrow transplantation to immunosuppressive therapy in children with acquired severe aplastic anemia. Experimental Hematology (Charlottesville) 22(8): 690, 1994

Severe acquired aplastic anemia: historical outcome of patients treated by allogeneic bone marrow transplantation from matched sibling donors. A study by the Spanish Group for Bone Marrow Transplantation in Children (GETMON). Anales de Pediatria 69(1): 5-9, 2008

Treatment of acquired aplastic anemia in children bone marrow transplantation or immunosuppressive therapy. Journal of Cellular Biochemistry Supplement (14 PART A): 288, 1990

Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: Multicenter trial. International Journal of Hematology 78(2): 133-138, August, 2003